Impact of HSP90 Inhibitor NVP-BEP800 on SRC Kinase Stability in T- and B-ALL

Overview

The HSP90 inhibitor NVP-BEP800 effectively destabilizes SRC family kinases LCK and LYN in T-cell and B-cell acute lymphoblastic leukemia (ALL), respectively, leading to reduced leukemia cell viability and proliferation. This effect was demonstrated both in vitro using primary patient samples and in vivo in xenografted mouse models.

Background

Acute lymphoblastic leukemia (ALL) is a malignancy characterized by the proliferation of immature lymphocyte precursors, affecting predominantly children but also adults. Despite high remission rates, long-term survival remains suboptimal, necessitating novel therapeutic strategies. Heat shock protein 90 (HSP90) is a molecular chaperone overexpressed in leukemia cells, supporting the stability of oncogenic proteins including SRC family kinases (SFKs) such as LCK in T-ALL and LYN in B-ALL. Targeting HSP90 has shown promise in various hematological malignancies, but its role in ALL, particularly via inhibition of SFKs, requires further exploration.

Data Highlights

Key Findings

• NVP-BEP800 targets the ATP-binding pocket of HSP90β, leading to destabilization of SRC family kinases LCK in T-ALL and LYN in B-ALL.
• HSP90 inhibition by NVP-BEP800 reduces viability of primary T-ALL and B-ALL cells isolated from patient bone marrow and peripheral blood samples.
• In xenografted mouse models, NVP-BEP800 treatment significantly inhibits leukemia cell development and proliferation.
• HSP90 expression is elevated in both T-ALL and B-ALL patient samples and correlates with poor prognosis, supporting HSP90 as a therapeutic target.
• Previous HSP90 inhibitors demonstrated efficacy in hematological malignancies, but NVP-BEP800 uniquely affects SFK clients critical for ALL cell survival.

Clinical Implications

NVP-BEP800 represents a promising therapeutic agent for both T-ALL and B-ALL by targeting HSP90-dependent SRC family kinases essential for leukemia cell survival. Its ability to reduce leukemia proliferation in preclinical models suggests potential for incorporation into treatment regimens, possibly improving outcomes and reducing reliance on intensive chemotherapy. Further clinical evaluation is warranted to assess safety and efficacy in patients.

Conclusion

The study establishes NVP-BEP800 as an effective HSP90 inhibitor that disrupts SRC kinase stability, impairing proliferation of T- and B-ALL cells. These findings support further development of HSP90-targeted therapies to improve ALL treatment outcomes.

References

1. Original Article -- Impact of HSP90 Inhibitor NVP-BEP800 on SRC Kinase Stability and Proliferation of T-cell and B-cell Acute Lymphoblastic Leukemia